1. Home
  2. SRRK vs LYFT Comparison

SRRK vs LYFT Comparison

Compare SRRK & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$47.49

Market Cap

6.8B

Sector

Health Care

ML Signal

HOLD

Logo Lyft Inc.

LYFT

Lyft Inc.

HOLD

Current Price

$15.73

Market Cap

5.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRRK
LYFT
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.8B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SRRK
LYFT
Price
$47.49
$15.73
Analyst Decision
Strong Buy
Buy
Analyst Count
13
29
Target Price
$56.17
$20.07
AVG Volume (30 Days)
1.0M
11.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11250.00
EPS
N/A
0.04
Revenue
N/A
$6,316,261,000.00
Revenue This Year
N/A
$17.33
Revenue Next Year
$534.24
$12.29
P/E Ratio
N/A
$396.50
Revenue Growth
N/A
9.16
52 Week Low
$27.07
$12.46
52 Week High
$58.49
$25.54

Technical Indicators

Market Signals
Indicator
SRRK
LYFT
Relative Strength Index (RSI) 39.11 54.80
Support Level $45.83 $12.93
Resistance Level $48.23 $16.52
Average True Range (ATR) 2.20 0.67
MACD -0.65 -0.02
Stochastic Oscillator 5.15 64.19

Price Performance

Historical Comparison
SRRK
LYFT

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About LYFT Lyft Inc.

Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.

Share on Social Networks: